A phase IIa, randomized, open-label study evaluating the safety and efficacy of CreaVax-RA combined with traditional disease modifying anti-rheumatic drugs (DMARDs) therapy in patients with moderate to severe active rheumatoid arthritis despite DMARDs therapy
Latest Information Update: 18 Sep 2019
At a glance
- Drugs Dendritic cell vaccine-CreaGene (Primary) ; Disease-modifying antirheumatics
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms RIMMUNERA
- Sponsors JW CreaGene
- 16 Dec 2013 New trial record